High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB). In line with American Association for the Study of Liver Diseases guidelines, adefovir dipivoxil (ADV) add-on therapy is recommended in the case of lamivudine resistance, while tenofovir disoproxil fumarate (TDF) is recommended for ADV or entecavir (ETV)resistance. TDF is currently not available in Korea. ADV+ETV combination therapy may be a viable alternative to TDF in patients with either ADV or ETV resistance. However, the efficacy of ADV+ETV combination therapy in patients with CHB and multidrug resistance is unclear. This study investigated the efficacy of ADV+ETV combination therapy in patients with multidrug resistance. Methods: Twenty-five patients were enrolled and were administered ADV+ETV combination therapy for at least 6 months. Blood was drawn at baseline and at 3, 6, 9, and 12 months after commencing treatment,and the following blood parameters were analyzed: alanine transaminase, hepatitis B e-antigen (HBeAg), anti-hepatitis B e-antigen, and hepatitis B virus (HBV) DNA levels. The initial virological response (IVR) was defined as an HBV DNA level of <4 log10 copies/mL after 6 months of combination therapy. Results: The IVR rate was 76%. The proportion of patients with a high viral load (≥5.0 log) dropped from 76% at baseline to only 5% after 6 months of treatment. The biochemical response rate during the first 6 months was 71%. HBeAg was lost in 2 patients (10%). Conclusions: ADV+ETV combination therapy induced a good IVR in CHB patients who were refractory to more than 2 antiviral agents. This regimen may be a good alternative to TDF in Korea, where that drug is not available. (Korean J Hepatol 2012;18:75-83)
Abstract
Background/Aims: Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB). In line with American Association for the Study of Liver Diseases guidelines, adefovir dipivoxil (ADV) add-on therapy is recommended in the case of lamivudine resistance, while tenofovir disoproxil fumarate (TDF) is recommended for ADV or entecavir (ETV)resistance. TDF is currently not available in Korea. ADV+ETV combination therapy may be a viable alternative to TDF in patients with either ADV or ETV resistance. However, the efficacy of ADV+ETV combination therapy in patients with CHB and multidrug resistance is unclear. This study investigated the efficacy of ADV+ETV combination therapy in patients with multidrug resistance. Methods: Twenty-five patients were enrolled and were administered ADV+ETV combination therapy for at least 6 months. Blood was drawn at baseline and at 3, 6, 9, and 12 months after commencing treatment,and the following blood parameters were analyzed: alanine transaminase, hepatitis B e-antigen (HBeAg), anti-hepatitis B e-antigen, and hepatitis B virus (HBV) DNA levels. The initial virological response (IVR) was defined as an HBV DNA level of <4 log10 copies/mL after 6 months of combination therapy. Results: The IVR rate was 76%. The proportion of patients with a high viral load (≥5.0 log) dropped from 76% at baseline to only 5% after 6 months of treatment. The biochemical response rate during the first 6 months was 71%. HBeAg was lost in 2 patients (10%). Conclusions: ADV+ETV combination therapy induced a good IVR in CHB patients who were refractory to more than 2 antiviral agents. This regimen may be a good alternative to TDF in Korea, where that drug is not available. (Korean J Hepatol 2012;18:75-83)
참고문헌 (19)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Ganem D, "Hepatitis B virus infection-natural history and clinical consequences", N Engl J Med, 350, pp.1118~1129 (2004)
- Wright TL, "Clinical aspects of hepatitis B virus infection", Lancet, 342, pp.1340~1344 (1993)
- Hansen BE, "Prediction of the response to peginterferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment", J Med Virol, 82, pp.1135~1142 (2010)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- 조지현, "B형간염바이러스 유전자형의 국내 분포에 대한 연구", Clinical and Molecular Hepatology, 15(2), pp.140~147 (2009), 대한간학회
- Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
- 이중민, "말디토프 질량 분석을 이용한 한국인의 B형간염 바이러스유전자형 및 임상적 의의에 대한 재평가", Clinical and Molecular Hepatology, 10(2004), pp.260~270 (2004), 대한간학회
- Lim YS, "Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside", nucleotide analogues, 2012, pp.17, 53~60
- Lai CL, "The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points", Ann Intern Med, 147, pp.58~61 (2007)
- Locarnini S, "Management of antiviral resistance in patients with chronic hepatitis B", Antivir Ther, 9, pp.679~693 (2004)
- Cho SW, "Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance", J Viral Hepat, 17, pp.171~177 (2010)
- Lok AS, "Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management", Hepatology, 46, pp.254~265 (2007)
- Lok AS, "A controlled trial of interferon with or without prednisone priming for chronic hepatitis B", Gastroenterology, 102, pp.2091~2097 (1992)
- Reijnders JG, "Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy", J Hepatol, 50, pp.674~683 (2009)
- Qi X, "In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents", Antivir Ther, 12, pp.355~362 (2007)
- Villet S, "Impact of hepatitis B virus rtA181V", T mutants on hepatitis B treatment failure, 2008, pp.48, 747~755